Gossamer Bio

formerly GossamerIPO

Transforming the lives of patients with pulmonary arterial hypertension.

Public · San Diego, United States · Founded 2017 · $912.0M raised

Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$912.0M
Last Round
$250.0M Private EquityAug 2026
Rounds
5
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Gossamer Bio, founded in 2015 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company listed on Nasdaq (GOSS). The company is focused on the development and commercialization of seralutinib, an inhaled kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). Gossamer raised $317 million in its 2019 IPO and has a global collaboration with the Chiesi Group for seralutinib development, providing milestone payments and cost reimbursements.

Summary

Gossamer Bio is a Biotech company based in San Diego, United States, founded in 2017. It has raised $912.0M in total across 5 rounds, most recently a $250.0M Private Equity round in Aug 2026. Investors include Hillhouse Capital, Hillhouse Capital Group and ARCH Venture Partners.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Private EquityPrivate EquityAug 2026
$250.0M

Sign up to see all 6 events

Funding: Series A through Private Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Gossamer Bio on Indexed.vc
<a href="https://indexed.vc/companies/gossamer-bio"><img src="https://indexed.vc/api/badge/company/gossamer-bio" alt="Gossamer Bio on Indexed.vc" width="260" height="76" /></a>